Oculus Innovative Sciences, Inc. Share Price Nasdaq
Equities
US67575P2074
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 1.47Cr 122.62Cr | Sales 2025 * | 1.79Cr 149.31Cr | Capitalization | 31.95L 27Cr |
---|---|---|---|---|---|
Net income 2024 * | -50L -42Cr | Net income 2025 * | -30L -25Cr | EV / Sales 2024 * | 0.22 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.18 x |
P/E ratio 2024 * |
-0.23
x | P/E ratio 2025 * |
-0.45
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Managers | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27/19/27 |
John Poggetto
DFI | Director of Finance/CFO | 53 | 01/02/01 |
Jerome Dvonch
DFI | Director of Finance/CFO | 56 | 08/20/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27/19/27 |
Jay Birnbaum
BRD | Director/Board Member | 79 | 20/07/20 |
Director/Board Member | 64 | 19/18/19 |
1st Jan change | Capi. | |
---|---|---|
+40.73% | 74TCr | |
+32.83% | 60TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
-5.52% | 21TCr | |
+6.17% | 16TCr | |
-0.45% | 16TCr |